Literature DB >> 2709054

Effect of cannabinoids on spasticity and ataxia in multiple sclerosis.

H M Meinck1, P W Schönle, B Conrad.   

Abstract

The chronic motor handicaps of a 30-year-old multiple sclerosis patient acutely improved while he smoked a marihuana cigarette. This effect was quantitatively assessed by means of clinical rating, electromyographic investigation of the leg flexor reflexes and electromagnetic recording of the hand action tremor. It is concluded that cannabinoids may have powerful beneficial effects on both spasticity and ataxia that warrant further evaluation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2709054     DOI: 10.1007/BF00314410

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  13 in total

1.  Evidence for a direct spinal mechanism in morphine-induced inhibition of nociceptive reflexes in humans.

Authors:  J C Willer; B Bussel
Journal:  Brain Res       Date:  1980-04-07       Impact factor: 3.252

2.  Electromagnetic articulography: use of alternating magnetic fields for tracking movements of multiple points inside and outside the vocal tract.

Authors:  P W Schönle; K Gräbe; P Wenig; J Höhne; J Schrader; B Conrad
Journal:  Brain Lang       Date:  1987-05       Impact factor: 2.381

3.  The perceived effects of marijuana on spinal cord injured males.

Authors:  M Dunn; R Davis
Journal:  Paraplegia       Date:  1974-11

4.  Cannabinoid-induced enhancement and depression of cat monosynaptic reflexes.

Authors:  A Tramposch; C Sangdee; D N Franz; R Karler; S A Turkanis
Journal:  Neuropharmacology       Date:  1981-06       Impact factor: 5.250

5.  Cannabis effect on spasticity in spinal cord injury.

Authors:  J Malec; R F Harvey; J J Cayner
Journal:  Arch Phys Med Rehabil       Date:  1982-03       Impact factor: 3.966

6.  Neuropharmacological investigations in the stiff-man syndrome.

Authors:  H M Meinck; B Conrad
Journal:  J Neurol       Date:  1986-11       Impact factor: 4.849

7.  A comparison of THC, nantradol, nabilone, and morphine in the chronic spinal dog.

Authors:  P E Gilbert
Journal:  J Clin Pharmacol       Date:  1981 Aug-Sep       Impact factor: 3.126

8.  Effects of delta 9-tetrahydrocannabinol on cat spinal motoneurons.

Authors:  S A Turkanis; R Karler
Journal:  Brain Res       Date:  1983-12-12       Impact factor: 3.252

9.  Tetrahydrocannabinol for tremor in multiple sclerosis.

Authors:  D B Clifford
Journal:  Ann Neurol       Date:  1983-06       Impact factor: 10.422

10.  The antinociceptive effects of intrathecally administered levonantradol and desacetyllevonantradol in the rat.

Authors:  T L Yaksh
Journal:  J Clin Pharmacol       Date:  1981 Aug-Sep       Impact factor: 3.126

View more
  24 in total

1.  Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome.

Authors:  Zinah Zamil Al-Ghezi; Philip Brandon Busbee; Hasan Alghetaa; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  Brain Behav Immun       Date:  2019-07-26       Impact factor: 7.217

Review 2.  Cannabinoids in clinical practice.

Authors:  E M Williamson; F J Evans
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

3.  Cannabinoids in pain management. Study was bound to conclude that cannabinoids had limited efficacy.

Authors:  E Russo
Journal:  BMJ       Date:  2001-11-24

Review 4.  Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.

Authors:  Vamsi Reddy; Dayton Grogan; Meenakshi Ahluwalia; Évila Lopes Salles; Pankaj Ahluwalia; Hesam Khodadadi; Katelyn Alverson; Andy Nguyen; Srikrishnan P Raju; Pankaj Gaur; Molly Braun; Fernando L Vale; Vincenzo Costigliola; Krishnan Dhandapani; Babak Baban; Kumar Vaibhav
Journal:  EPMA J       Date:  2020-04-15       Impact factor: 6.543

Review 5.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 6.  [Therapeutic use of cannabinoids in neurology].

Authors:  P Schwenkreis; M Tegenthoff
Journal:  Schmerz       Date:  2003-10       Impact factor: 1.107

Review 7.  The therapeutic potential of cannabinoids for movement disorders.

Authors:  Benzi Kluger; Piera Triolo; Wallace Jones; Joseph Jankovic
Journal:  Mov Disord       Date:  2015-02-04       Impact factor: 10.338

Review 8.  Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe?

Authors:  Shokouh Arjmand; Zohreh Vaziri; Mina Behzadi; Hassan Abbassian; Gary J Stephens; Mohammad Shabani
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 9.  Cannabinoids and multiple sclerosis.

Authors:  Roger G Pertwee
Journal:  Mol Neurobiol       Date:  2007-06-26       Impact factor: 5.590

Review 10.  Cannabinoids in multiple sclerosis: do they have a therapeutic role?

Authors:  Joep Killestein; Bernard M J Uitdehaag; Chris H Polman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.